Model mouse of Alzheimer's disease expressing FAD APP 716 and use thereof
AssigneeRiken
InventorsTakaomi Saido, Nobuhisa Iwata, Takashi Saito, Takahiro Suemoto, Jiro Takano
Life of this patent
Estimating the term…
Loading patent…
AssigneeRiken
InventorsTakaomi Saido, Nobuhisa Iwata, Takashi Saito, Takahiro Suemoto, Jiro Takano
Estimating the term…
The present invention provides a non-human model mammal of Alzheimer's disease (AD) containing chimeric amyloid precursor protein (APP) gene capable of producing human amyloid β peptide (Aβ) or a living part thereof, characterized in that Aβ42/Aβ40 ratio at 8-weeks-old is about 7-fold or more (about 140-fold or more in homozygote) higher compared to that of a corresponding wild-type mammal. Moreover, the present invention provides the mammal or a living part thereof, further characterized in that the level of APP expression is not significantly different compared to the corresponding wild-type mammal, and a screening method for a prophylactic and/or therapeutic drug for AD, a biomarker in biological fluids and molecular imaging of amyloid deposition or other pathological changes in the brain for an early diagnosis of AD using the mammal or a living part thereof.
A transgenic mouse or living part thereof comprising a chimeric APP gene encoding a human Aβ having a FAD mutation and differing from the human APP gene of SEQ ID NO:
A knock-in mouse or living part thereof comprising a chimeric APP gene that encodes human Aβ having a Swedish mutation and differs from the human APP gene of SEQ ID NO:
Dependencies are inferred from the claim text.